To evaluate Multiple Independent Current Control (MICC) perception and sub-perception based programming at Dorsal Column (DC) targets and Dorsal Root (DR) targets for focal foot, knee, or groin pain relief.
ID
Source
Brief title
Condition
- Spinal cord and nerve root disorders
- Nervous system, skull and spine therapeutic procedures
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
There is no primary endpoint. Collected data will be used to increase the
understanding of the therapy, guide product development and help define the
best practice for programming patients with focal foot, knee, or groin pain
using Spinal Cord Stimulation devices.
Secondary outcome
Exploratory endpoints:
- Change in average foot, knee, or groin pain and overall pain intensity from
Baseline to end of each Period and End of Study (Pain Diary, NRS)
- Treatment Satisfaction at end of each Period and End of Study (PSWT)
- Global impression of change at end of each Period and End of Study (PGIC)
- Change in disability from Baseline to end of each Period and End of Study
(ODI)
- Change in Quality of life from Baseline to end of each Period and End of
Study (EQ-5D-5L)
- Change in sleep quality from Baseline to end of each Period and End of Study
(PSQI)
- Patient preferred program at end of Periods 2 and 4 (Preference
Questionnaire)
- Physician preferred program at end of Periods 2 and 4 (Preference
Questionnaire)
- Pain/paresthesia overlap for each tested perception based configuration
(Pain/Paresthesia drawings)
Safety parameters:
- Rate of device and/or procedure related non-serious adverse events
- Rate of device and/or procedure related serious adverse events
- Rate of unanticipated adverse device effects
Background summary
Chronic intractable pain is often defined as pain persisting for at least 6
months which has not responded to conservative treatment(s). The pain may be
due to current or past nerve injury and can result in significant disability,
reduced work productivity, reduced quality of life, and significant cost burden.
Early treatments for chronic pain typically include over *the-counter and
prescription medications. Later treatments like physical therapy and
interventional pain procedures (e.g. intraspinal injections, vertebroplasty,
pulsed RF) are attempted, sometimes followed by chronic high dose opioids and
back surgery, if indicated.
If back surgery is unsuccessful in relieving the chronic pain, the patient can
be labeled as having failed back surgery syndrome (FBSS). Spinal cord
stimulation is an option in the well-selected patient with chronic low back
and/or leg pain. Such pain can lead to a number of co-morbidities, including
reduced health-related quality of life, reduced ability to engage in activities
of daily living, increased disability, increased emotional depression, and
weight gain due to the adoption of a sedentary lifestyle.
Spinal cord stimulation (SCS) is effective for chronic intractable pain
associated with a variety of conditions, including, but not limited to: FBSS,
complex regional pain syndrome, low back pain and leg pain.
SCS is a less invasive treatment option for FBSS but has generally been
reserved for patients who have failed multiple, and indeed all possible, repeat
operations. With SCS, an implanted pulse generator (IPG) delivers electrical
current to electrode(s) implanted in the epidural space. This electrical
current causes activation of nerves and can be programmed to direct
stimulation to the nerves innervating the painful location, resulting in a
reduction of the intensity of that pain.
Traditionally, SCS has relied on the understanding that to achieve pain relief,
dorsal column stimulation-induced paresthesia (perceptionbased stimulation) has
to be generated overlying the area of pain in order to successfully treat pain.
However, recent studies indicate that effective pain relief may be obtained by
employing stimulation without paresthesia (subperception based stimulation).
Also outcomes of another stimulation paradigm (burst-stimulation) without
paresthesia induction has been reported.
Lateral stimulation outcomes, where leads are placed laterally in the epidural
space to target nerve roots, have been previously reported for foot pain.
This study will evaluated different types of stimulation. Perception based and
subperception based spinal cord and nerve root stimulation is evaluated.
Study objective
To evaluate Multiple Independent Current Control (MICC) perception and
sub-perception based programming at Dorsal Column (DC) targets and Dorsal Root
(DR) targets for focal foot, knee, or groin pain relief.
Study design
Multi-center, double blind randomized controlled cross-over study.
Intervention
All participants will be implanted with 1 or 2 additional electrodes at the
nerve roots.
Main study cohort:
Subjects from the main study cohort will be randomized twice. First
randomization takes place before start of the perception based stimulation. A
second randomization will take pace before the start of the subperceptionbased
stimulation.
Main study cohort and substudy cohort:
Subjects will be asked to implement wash out periods for maximum 7 days.
Study burden and risks
Patients who receive the device are subject to the same risks as patients
outside of this study who receive the same or other similar commercial devices.
However, there are additional risks related to the implantation of up to 2
electrodes at the lower level of the spine compared with the implantation of
the electrodes at the standard level of the spine. In addition, there is also a
higher risk related to the number of electrodes implanted in the study (up to 4
electrodes) compared with the number of electrodes implanted as standard of
care (2 electrodes only).
During the study the patients will be treated with different types of
stimulation. Patients may find certain stimulation parameters to be less
effective than others at reducing their pain, and they might experience
stimulation-related side effects including, but not limited to, muscle spasm
and discomfort, which the physician will address as per standard of care.
This study is set up to collect data through questionnaires and diary. To
complete these questionnaires, patients may spend additional time at the
hospital compared to standard of care.
For those follow up visits where programming is performed and questionnaires
are completed, patients may spend up to 1,5 hours additional time at the
hospital. Patients may find it difficult, uncomfortable or tiresome to complete
study visits, the pain diary and/or questionnaires.
Considering the above burden and risks, the conduct of this study is justified.
Vestastraat 6
Kerkrade 6468 EX
NL
Vestastraat 6
Kerkrade 6468 EX
NL
Listed location countries
Age
Inclusion criteria
IC1. Average unilateral foot, knee, or groin pain (of neuropathic origin only)
intensity of 6 or greater on a 0-10 numerical rating scale at Baseline Visit
based on 7-day average NRS score
IC2. Subject signed a valid, EC-approved informed consent form (ICF)
IC3. Willing and able to comply with all protocol-required procedures and
assessments/evaluations
IC4. At least 80% pain/paresthesia overlap during on-table testing for each set
of implanted leads
Patients with at least 80% pain/paresthesia overlap at DC/DR leads only will be
part of the DC/DR subgroup
IC5. If taking prescription opioids for primary chronic pain complaint (low
back and/or leg and/or foot and/or knee and/or groin pain), must have been on a
stable prescription (same drug(s) and dose(s)) 30 days prior to Screening
IC6. Consumed an average total daily morphine equivalent of *100 mg during the
30 days prior to Screening
IC7. 18 years of age or older when written informed consent is obtained
Exclusion criteria
EC1. Significant cognitive impairment at Screening that, in the opinion of the
Investigator, would reasonably be expected to impair the study candidates to
participate in the study
EC2. Previous spinal cord stimulation trial or is already implanted with an
active implantable device(s) (e.g. pacemaker, drug pump, implantable pulse
generator).
EC3. Participating (or intends to participate) in another drug or device
clinical trial that may influence the data that will be collected for this
study
EC4. Currently on any anticoagulant medications that cannot be discontinued
during perioperative period
EC5. A female who is pregnant, is breastfeeding, or is of childbearing
potential and planning to get pregnant during the course of the study or not
using adequate contraception.
EC6. Clinically significant lumbosacral stenosis which would interfere with
lead placement
EC7. Prior history of lumbar-sacral spine fusion
Design
Recruitment
Medical products/devices used
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
ClinicalTrials.gov | NCT04073446 |
CCMO | NL76864.091.21 |